2025 Q3 -tulosraportti
112 päivää sitten1 t 18 min
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15,11VWAP
Alin
14,04VaihtoMäärä
40,1 2 708 912
VWAP
Ylin
15,11Alin
14,04VaihtoMäärä
40,1 2 708 912
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 11.8.2025 | |
| 2025 Q1 -tulosraportti | 1.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16.1.Summit Therapeutics – Important milestone for ivonescimab and the company's future On January 12, 2026, Summit Therapeutics announced one of its most important news to date: the company has now submitted a so-called Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its drug ivonescimab in combination with chemotherapy. The application concerns the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) in the second line or later – a patient group with high medical need and few effective alternatives. What is ivonescimab? Ivonescimab is a new type of drug – a bispecific antibody that combines two mechanisms of action: immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition). It is an innovative molecule designed to specifically target tumor tissue, thereby improving efficacy and reducing side effects. What did the study show? The global Phase III study HARMONi showed that patients treated with ivonescimab + chemotherapy had a significantly improved progression-free survival (PFS) compared to chemotherapy alone. This is the first time an immunotherapy has shown efficacy in this patient group, where previous PD-1 inhibitors like Keytruda have not succeeded. It is a clear statement of strength. What does this mean for us shareholders? - Summit has now taken a decisive step towards becoming a commercial pharmaceutical company. - FDA decision expected Q4 2026 – a clear trigger. - If approved, ivonescimab will be the first immune-based drug with documented efficacy in this indication. - The market potential in the USA is estimated at over 14 000 patients per year – with a potential value in the billion-dollar range. - Summit has a strong cash position (~$710M) to finance launch and further development. - Several ongoing Phase III studies (HARMONi-3, HARMONi-7, HARMONi-GI3) broaden the area of use – including first-line NSCLC and colorectal cancer. - Ivonescimab is already approved in China (under the name Cardieva®), which strengthens credibility. For new shareholders: This is a classic example of a biotech company transitioning from research to market. The BLA submission is the formal step before a drug can be sold in the USA. It is a process that takes approximately 10 months, and if the FDA approves the application, the door opens to revenues, partnerships, and potential acquisition interest. Conclusion: Summit has delivered on an important milestone. We have a drug with clinically proven efficacy in a difficult-to-treat form of cancer, a regulatory process underway, and a growing pipeline. For us shareholders, this means that 2026 could be a decisive year – with several potential value drivers in sight.- ·11.1.Summit Therapeutics – What do the employee stock options mean for us shareholders? On January 9, 2026, Summit announced that it had granted 214,331 stock options to 17 new hires, with an exercise price of $18.66 and a vesting period (vesting) of 4 years. This is a common measure according to Nasdaq Rule 5635(c)(4), which allows companies to provide incentives to new hires without needing shareholder approval. What does this mean for us as shareholders? -Negligible dilution: 214k shares correspond to less than 0.03 % of the total number of outstanding shares (~743 million). So, there is no significant risk of dilution of our holdings. - Long-term loyalty & commitment: The options vest in equal parts over four years. This means that the new hires must remain and contribute for a longer period to access their entire option package. This is a smart way to create stronger commitment, loyalty, and a shared focus on building value over time – something that benefits both the company and us shareholders. - Strategic growth signal: That they are recruiting and simultaneously offering multi-year incentives indicates that Summit is building up its team to meet future milestones – e.g., clinical trials and regulatory approvals. - Alignment of interests: The new hires only benefit from this if the share price rises – just like us. This creates a clear link between their performance and our shareholder value. -Conclusion: This is a cautiously positive sign. It does not directly affect the company's fundamental value, but shows that Summit is investing in its future capacity. If the new recruits deliver on their goals, it can ultimately strengthen the company's position – and our shareholder value. P.s. A company doesn't do this without having something going on….. a shift!
- ·22.12.2025SUMMIT THERAPEUTICS – FROM R&D COMPANY TO GLOBAL ONCOLOGY PLAYER? Nov 7, 2025 | Phase III results from HARMONi-A presented at SITC 2025 Summit Therapeutics has delivered its biggest news to date – and it could be the starting shot for a new era. Together with Chinese Akeso, they have presented the final results from the Phase III study HARMONi-A, and it is nothing short of a breakthrough. What is it about? The study tested ivonescimab – a new type of bispecific antibody that combines immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition) – in combination with chemotherapy for patients with EGFR-mutated lung cancer who no longer respond to TKI treatment. The results speak for themselves: - Median overall survival: Ivonescimab + chemo: 16.8 months Chemo alone: 14.1 months - Hazard ratio (OS): 0.74 → 26% lower risk of death - Statistically significant (p=0.019) - >40,000 patients already treated in China 🇨🇳 Approved in China (May 2024) + NRDL-listed 🇺🇸 FDA Fast Track status → BLA application planned Q4 2025 Why is this so big for Summit? Summit has been a pure R&D company – without commercial products. Now they have: - A product with proven survival benefit - A unique mechanism of action that succeeds where other immunotherapies have failed - A regulatory path into the USA and Europe - Several ongoing Phase III studies globally (e.g., against Keytruda) And not least – strong owner support: Summit's largest owner and chairman of the board is Robert W. Duggan – a billionaire with an impressive track record in biotech. He was previously CEO and largest owner of Pharmacyclics, which was sold to AbbVie for 21 billion USD. Duggan has invested hundreds of millions of dollars in Summit and is deeply involved in the company's strategy. His financial muscle and experience give Summit both stability and credibility ahead of a potential commercialization. Conclusion: This is a milestone. Summit is on the threshold of becoming a global player in oncology. If FDA approval comes in 2026, ivonescimab could become the new standard in second-line treatment of EGFR-mutated NSCLC – a market with great need and low competition. This is not just a data point – it is a strategic shift. Summit is moving from the lab to the market. With Duggan at the helm and a rapidly growing pipeline, the potential is enormous.
- ·20.10.2025Yesterday (October 19th) Summit Therapeutics released a press release https://www.smmttx.com/wp-content/uploads/2026/10/2025_PR_1019_ESMO-HARMONi-6-Data-_-FINAL.pdf. This press release announces a major clinical breakthrough in lung cancer treatment. The drug ivonescimab (from Akeso and Summit Therapeutics) has been shown in a large Phase III study (HARMONi-6) to be superior to the current gold standard for a specific patient group. Here are the key points: The New Mechanism: Ivonescimab is not just another immunotherapy. It is a bispecific antibody, which means it is designed to attack cancer in two ways at once: PD-1 blockade: Activates the body's own immune system to attack cancer cells (the same mechanism as blockbusters like Keytruda). VEGF blockade: Prevents the tumor from forming new blood vessels, which effectively "starves" it (same mechanism as Avastin). The breakthrough (This is the key): The study was a direct comparison ("head-to-head") against the best available treatment today: a PD-1 inhibitor (Tislelizumab) plus chemotherapy. Ivonescimab won this comparison by a wide margin. Effect: The risk of the disease getting worse (progression) or the patient dying was reduced by 40%. Summary conclusion: This is the first time a Phase III study has shown that a new treatment is significantly better than the current gold standard (PD-1 + chemotherapy) for this patient group. The dual PD-1/VEGF effect appears to be a superior strategy. My reflection on the press release from Summit Therapeutics (SMMT) and their partner Akeso regarding their Phase III study (HARMONi-6) for the drug ivonescimab. The data, presented at ESMO and published in The Lancet, is exceptionally strong and represents a potential paradigm shift in the treatment of lung cancer (squamous NSCLC). Here is my immediate analysis of the possible scenarios: 1. The Positive Scenario (Opportunity) This is the first drug ever to be shown to be significantly better than the current gold standard (PD-1 inhibitors such as Keytruda + chemotherapy) in a Phase III trial. Superior Efficacy: Ivonescimab + chemotherapy reduced the risk of disease progression or death by 40% compared to standard therapy. Extended Disease-Free Survival: Patients achieved 11.14 months of progression-free survival (PFS), compared to just 6.90 months for standard therapy. This is a massive clinical gain. Blockbuster potential: If this result can be replicated globally, ivonescimab has the potential to replace the current standard of care and become the new global first-line treatment, representing a multi-billion dollar (USD) market. Broad Use: The drug is effective regardless of the patient's PD-L1 status, making it easy for doctors to prescribe to a broad patient population without the need for additional testing. 2. The Downside (Risk & Catch) The most important limitation, defining the entire investment risk, is that HARMONi-6 is a 100% Chinese study, sponsored and analyzed by the Chinese partner Akeso. Regulatory Obstacle: Neither the FDA (US) nor the EMA (Europe) will approve a drug for the global market based on this data alone. It all depends on HARMONi-3: The global value of Summit (SMMT) is entirely dependent on the ongoing global HARMONi-3 study. This study must replicate (repeat) the strong results from China. Long Timeline: We won't know the answer soon. Data from HARMONi-3 is not expected until the second half of 2026. This means a long wait and high risk until then. 3. Likely Scenarios Ahead Short Term (6-12 months): Akeso gets fast-track approval in China based on the HARMONi-6 data. Ivonescimab becomes the new standard of care in China, generating revenue there. Medium Term (2025-2026): The market will be extremely focused on the recruitment rate in the global HARMONi-3 study. Any delays will punish the stock. Competitors (Merck, BMS, etc.) will accelerate their own programs to try to catch up. Long Term (H2 2026 and beyond): Everything is decided. If HARMONi-3 succeeds: Summit has one of the biggest oncology successes in years and the stock revalues accordingly. If HARMONi-3 fails: The drug remains a Chinese concern and the global value for Summit is minimal. Summary: Today's data is a huge proof-of-concept that proves the drug's mechanism (PD-1/VEGF) is superior to the current standard. The potential is huge, but the risk is equally great and rests entirely on whether the results can be replicated in the global HARMONi-3 trial in 2026.
- ·9.10.2025An interesting case in oncology – Summit Therapeutics. The company is in late clinical phase with a unique drug candidate and has several triggers that could drive the share price significantly in the coming year. What does the company do? Summit is developing ivonescimab – a bispecific antibody that combines PD-1 and VEGF blockade in one molecule. It has shown better efficacy than Keytruda in certain lung cancer groups and is already approved in China. Highlights that speak for success: - Positive phase III data (PFS) globally - Two regulatory approvals in China - Collaboration with Pfizer and Revolution Medicines - Management with a proven track record, Robert Duggan (75%) and Maky Zanganeh (5%) are both owners and co-CEOs. They previously built Pharmacyclics (Imbruvica) which was sold for $21 billion. Their experience and capital strength are a great asset. - Strong cash ($298 mn) and insider support - First in class with PD-1/VEGF bispecific - Presentations at WCLC, ASCO, ESMO - Rumors of licensing deal with AstraZeneca Financial situation: Runway ~12–18 months. Issue risk exists, but insiders have historically supported capital raising. Summit is well positioned to raise capital on its own terms. Triggers in the coming year: - Interim data from HARMONi-3/HARMONi-7 - FDA acceptance of BLA application - Licensing deal with Big Pharma - New approvals or indications - Acquisition rumors, the 15 largest pharmaceutical companies have $535 billion on the sidelines for research and acquisitions - Presentations at ASCO/ESMO - Insider buyout or issuance with strong participation Summit is a classic high-risk/high-reward biotech case with exceptional upside if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
112 päivää sitten1 t 18 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.1.Summit Therapeutics – Important milestone for ivonescimab and the company's future On January 12, 2026, Summit Therapeutics announced one of its most important news to date: the company has now submitted a so-called Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its drug ivonescimab in combination with chemotherapy. The application concerns the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) in the second line or later – a patient group with high medical need and few effective alternatives. What is ivonescimab? Ivonescimab is a new type of drug – a bispecific antibody that combines two mechanisms of action: immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition). It is an innovative molecule designed to specifically target tumor tissue, thereby improving efficacy and reducing side effects. What did the study show? The global Phase III study HARMONi showed that patients treated with ivonescimab + chemotherapy had a significantly improved progression-free survival (PFS) compared to chemotherapy alone. This is the first time an immunotherapy has shown efficacy in this patient group, where previous PD-1 inhibitors like Keytruda have not succeeded. It is a clear statement of strength. What does this mean for us shareholders? - Summit has now taken a decisive step towards becoming a commercial pharmaceutical company. - FDA decision expected Q4 2026 – a clear trigger. - If approved, ivonescimab will be the first immune-based drug with documented efficacy in this indication. - The market potential in the USA is estimated at over 14 000 patients per year – with a potential value in the billion-dollar range. - Summit has a strong cash position (~$710M) to finance launch and further development. - Several ongoing Phase III studies (HARMONi-3, HARMONi-7, HARMONi-GI3) broaden the area of use – including first-line NSCLC and colorectal cancer. - Ivonescimab is already approved in China (under the name Cardieva®), which strengthens credibility. For new shareholders: This is a classic example of a biotech company transitioning from research to market. The BLA submission is the formal step before a drug can be sold in the USA. It is a process that takes approximately 10 months, and if the FDA approves the application, the door opens to revenues, partnerships, and potential acquisition interest. Conclusion: Summit has delivered on an important milestone. We have a drug with clinically proven efficacy in a difficult-to-treat form of cancer, a regulatory process underway, and a growing pipeline. For us shareholders, this means that 2026 could be a decisive year – with several potential value drivers in sight.
- ·11.1.Summit Therapeutics – What do the employee stock options mean for us shareholders? On January 9, 2026, Summit announced that it had granted 214,331 stock options to 17 new hires, with an exercise price of $18.66 and a vesting period (vesting) of 4 years. This is a common measure according to Nasdaq Rule 5635(c)(4), which allows companies to provide incentives to new hires without needing shareholder approval. What does this mean for us as shareholders? -Negligible dilution: 214k shares correspond to less than 0.03 % of the total number of outstanding shares (~743 million). So, there is no significant risk of dilution of our holdings. - Long-term loyalty & commitment: The options vest in equal parts over four years. This means that the new hires must remain and contribute for a longer period to access their entire option package. This is a smart way to create stronger commitment, loyalty, and a shared focus on building value over time – something that benefits both the company and us shareholders. - Strategic growth signal: That they are recruiting and simultaneously offering multi-year incentives indicates that Summit is building up its team to meet future milestones – e.g., clinical trials and regulatory approvals. - Alignment of interests: The new hires only benefit from this if the share price rises – just like us. This creates a clear link between their performance and our shareholder value. -Conclusion: This is a cautiously positive sign. It does not directly affect the company's fundamental value, but shows that Summit is investing in its future capacity. If the new recruits deliver on their goals, it can ultimately strengthen the company's position – and our shareholder value. P.s. A company doesn't do this without having something going on….. a shift!
- ·22.12.2025SUMMIT THERAPEUTICS – FROM R&D COMPANY TO GLOBAL ONCOLOGY PLAYER? Nov 7, 2025 | Phase III results from HARMONi-A presented at SITC 2025 Summit Therapeutics has delivered its biggest news to date – and it could be the starting shot for a new era. Together with Chinese Akeso, they have presented the final results from the Phase III study HARMONi-A, and it is nothing short of a breakthrough. What is it about? The study tested ivonescimab – a new type of bispecific antibody that combines immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition) – in combination with chemotherapy for patients with EGFR-mutated lung cancer who no longer respond to TKI treatment. The results speak for themselves: - Median overall survival: Ivonescimab + chemo: 16.8 months Chemo alone: 14.1 months - Hazard ratio (OS): 0.74 → 26% lower risk of death - Statistically significant (p=0.019) - >40,000 patients already treated in China 🇨🇳 Approved in China (May 2024) + NRDL-listed 🇺🇸 FDA Fast Track status → BLA application planned Q4 2025 Why is this so big for Summit? Summit has been a pure R&D company – without commercial products. Now they have: - A product with proven survival benefit - A unique mechanism of action that succeeds where other immunotherapies have failed - A regulatory path into the USA and Europe - Several ongoing Phase III studies globally (e.g., against Keytruda) And not least – strong owner support: Summit's largest owner and chairman of the board is Robert W. Duggan – a billionaire with an impressive track record in biotech. He was previously CEO and largest owner of Pharmacyclics, which was sold to AbbVie for 21 billion USD. Duggan has invested hundreds of millions of dollars in Summit and is deeply involved in the company's strategy. His financial muscle and experience give Summit both stability and credibility ahead of a potential commercialization. Conclusion: This is a milestone. Summit is on the threshold of becoming a global player in oncology. If FDA approval comes in 2026, ivonescimab could become the new standard in second-line treatment of EGFR-mutated NSCLC – a market with great need and low competition. This is not just a data point – it is a strategic shift. Summit is moving from the lab to the market. With Duggan at the helm and a rapidly growing pipeline, the potential is enormous.
- ·20.10.2025Yesterday (October 19th) Summit Therapeutics released a press release https://www.smmttx.com/wp-content/uploads/2026/10/2025_PR_1019_ESMO-HARMONi-6-Data-_-FINAL.pdf. This press release announces a major clinical breakthrough in lung cancer treatment. The drug ivonescimab (from Akeso and Summit Therapeutics) has been shown in a large Phase III study (HARMONi-6) to be superior to the current gold standard for a specific patient group. Here are the key points: The New Mechanism: Ivonescimab is not just another immunotherapy. It is a bispecific antibody, which means it is designed to attack cancer in two ways at once: PD-1 blockade: Activates the body's own immune system to attack cancer cells (the same mechanism as blockbusters like Keytruda). VEGF blockade: Prevents the tumor from forming new blood vessels, which effectively "starves" it (same mechanism as Avastin). The breakthrough (This is the key): The study was a direct comparison ("head-to-head") against the best available treatment today: a PD-1 inhibitor (Tislelizumab) plus chemotherapy. Ivonescimab won this comparison by a wide margin. Effect: The risk of the disease getting worse (progression) or the patient dying was reduced by 40%. Summary conclusion: This is the first time a Phase III study has shown that a new treatment is significantly better than the current gold standard (PD-1 + chemotherapy) for this patient group. The dual PD-1/VEGF effect appears to be a superior strategy. My reflection on the press release from Summit Therapeutics (SMMT) and their partner Akeso regarding their Phase III study (HARMONi-6) for the drug ivonescimab. The data, presented at ESMO and published in The Lancet, is exceptionally strong and represents a potential paradigm shift in the treatment of lung cancer (squamous NSCLC). Here is my immediate analysis of the possible scenarios: 1. The Positive Scenario (Opportunity) This is the first drug ever to be shown to be significantly better than the current gold standard (PD-1 inhibitors such as Keytruda + chemotherapy) in a Phase III trial. Superior Efficacy: Ivonescimab + chemotherapy reduced the risk of disease progression or death by 40% compared to standard therapy. Extended Disease-Free Survival: Patients achieved 11.14 months of progression-free survival (PFS), compared to just 6.90 months for standard therapy. This is a massive clinical gain. Blockbuster potential: If this result can be replicated globally, ivonescimab has the potential to replace the current standard of care and become the new global first-line treatment, representing a multi-billion dollar (USD) market. Broad Use: The drug is effective regardless of the patient's PD-L1 status, making it easy for doctors to prescribe to a broad patient population without the need for additional testing. 2. The Downside (Risk & Catch) The most important limitation, defining the entire investment risk, is that HARMONi-6 is a 100% Chinese study, sponsored and analyzed by the Chinese partner Akeso. Regulatory Obstacle: Neither the FDA (US) nor the EMA (Europe) will approve a drug for the global market based on this data alone. It all depends on HARMONi-3: The global value of Summit (SMMT) is entirely dependent on the ongoing global HARMONi-3 study. This study must replicate (repeat) the strong results from China. Long Timeline: We won't know the answer soon. Data from HARMONi-3 is not expected until the second half of 2026. This means a long wait and high risk until then. 3. Likely Scenarios Ahead Short Term (6-12 months): Akeso gets fast-track approval in China based on the HARMONi-6 data. Ivonescimab becomes the new standard of care in China, generating revenue there. Medium Term (2025-2026): The market will be extremely focused on the recruitment rate in the global HARMONi-3 study. Any delays will punish the stock. Competitors (Merck, BMS, etc.) will accelerate their own programs to try to catch up. Long Term (H2 2026 and beyond): Everything is decided. If HARMONi-3 succeeds: Summit has one of the biggest oncology successes in years and the stock revalues accordingly. If HARMONi-3 fails: The drug remains a Chinese concern and the global value for Summit is minimal. Summary: Today's data is a huge proof-of-concept that proves the drug's mechanism (PD-1/VEGF) is superior to the current standard. The potential is huge, but the risk is equally great and rests entirely on whether the results can be replicated in the global HARMONi-3 trial in 2026.
- ·9.10.2025An interesting case in oncology – Summit Therapeutics. The company is in late clinical phase with a unique drug candidate and has several triggers that could drive the share price significantly in the coming year. What does the company do? Summit is developing ivonescimab – a bispecific antibody that combines PD-1 and VEGF blockade in one molecule. It has shown better efficacy than Keytruda in certain lung cancer groups and is already approved in China. Highlights that speak for success: - Positive phase III data (PFS) globally - Two regulatory approvals in China - Collaboration with Pfizer and Revolution Medicines - Management with a proven track record, Robert Duggan (75%) and Maky Zanganeh (5%) are both owners and co-CEOs. They previously built Pharmacyclics (Imbruvica) which was sold for $21 billion. Their experience and capital strength are a great asset. - Strong cash ($298 mn) and insider support - First in class with PD-1/VEGF bispecific - Presentations at WCLC, ASCO, ESMO - Rumors of licensing deal with AstraZeneca Financial situation: Runway ~12–18 months. Issue risk exists, but insiders have historically supported capital raising. Summit is well positioned to raise capital on its own terms. Triggers in the coming year: - Interim data from HARMONi-3/HARMONi-7 - FDA acceptance of BLA application - Licensing deal with Big Pharma - New approvals or indications - Acquisition rumors, the 15 largest pharmaceutical companies have $535 billion on the sidelines for research and acquisitions - Presentations at ASCO/ESMO - Insider buyout or issuance with strong participation Summit is a classic high-risk/high-reward biotech case with exceptional upside if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15,11VWAP
Alin
14,04VaihtoMäärä
40,1 2 708 912
VWAP
Ylin
15,11Alin
14,04VaihtoMäärä
40,1 2 708 912
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 11.8.2025 | |
| 2025 Q1 -tulosraportti | 1.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
2025 Q3 -tulosraportti
112 päivää sitten1 t 18 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 20.10.2025 | |
| 2025 Q2 -tulosraportti | 11.8.2025 | |
| 2025 Q1 -tulosraportti | 1.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 | |
| 2024 Q3 -tulosraportti | 30.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.1.Summit Therapeutics – Important milestone for ivonescimab and the company's future On January 12, 2026, Summit Therapeutics announced one of its most important news to date: the company has now submitted a so-called Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its drug ivonescimab in combination with chemotherapy. The application concerns the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) in the second line or later – a patient group with high medical need and few effective alternatives. What is ivonescimab? Ivonescimab is a new type of drug – a bispecific antibody that combines two mechanisms of action: immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition). It is an innovative molecule designed to specifically target tumor tissue, thereby improving efficacy and reducing side effects. What did the study show? The global Phase III study HARMONi showed that patients treated with ivonescimab + chemotherapy had a significantly improved progression-free survival (PFS) compared to chemotherapy alone. This is the first time an immunotherapy has shown efficacy in this patient group, where previous PD-1 inhibitors like Keytruda have not succeeded. It is a clear statement of strength. What does this mean for us shareholders? - Summit has now taken a decisive step towards becoming a commercial pharmaceutical company. - FDA decision expected Q4 2026 – a clear trigger. - If approved, ivonescimab will be the first immune-based drug with documented efficacy in this indication. - The market potential in the USA is estimated at over 14 000 patients per year – with a potential value in the billion-dollar range. - Summit has a strong cash position (~$710M) to finance launch and further development. - Several ongoing Phase III studies (HARMONi-3, HARMONi-7, HARMONi-GI3) broaden the area of use – including first-line NSCLC and colorectal cancer. - Ivonescimab is already approved in China (under the name Cardieva®), which strengthens credibility. For new shareholders: This is a classic example of a biotech company transitioning from research to market. The BLA submission is the formal step before a drug can be sold in the USA. It is a process that takes approximately 10 months, and if the FDA approves the application, the door opens to revenues, partnerships, and potential acquisition interest. Conclusion: Summit has delivered on an important milestone. We have a drug with clinically proven efficacy in a difficult-to-treat form of cancer, a regulatory process underway, and a growing pipeline. For us shareholders, this means that 2026 could be a decisive year – with several potential value drivers in sight.
- ·11.1.Summit Therapeutics – What do the employee stock options mean for us shareholders? On January 9, 2026, Summit announced that it had granted 214,331 stock options to 17 new hires, with an exercise price of $18.66 and a vesting period (vesting) of 4 years. This is a common measure according to Nasdaq Rule 5635(c)(4), which allows companies to provide incentives to new hires without needing shareholder approval. What does this mean for us as shareholders? -Negligible dilution: 214k shares correspond to less than 0.03 % of the total number of outstanding shares (~743 million). So, there is no significant risk of dilution of our holdings. - Long-term loyalty & commitment: The options vest in equal parts over four years. This means that the new hires must remain and contribute for a longer period to access their entire option package. This is a smart way to create stronger commitment, loyalty, and a shared focus on building value over time – something that benefits both the company and us shareholders. - Strategic growth signal: That they are recruiting and simultaneously offering multi-year incentives indicates that Summit is building up its team to meet future milestones – e.g., clinical trials and regulatory approvals. - Alignment of interests: The new hires only benefit from this if the share price rises – just like us. This creates a clear link between their performance and our shareholder value. -Conclusion: This is a cautiously positive sign. It does not directly affect the company's fundamental value, but shows that Summit is investing in its future capacity. If the new recruits deliver on their goals, it can ultimately strengthen the company's position – and our shareholder value. P.s. A company doesn't do this without having something going on….. a shift!
- ·22.12.2025SUMMIT THERAPEUTICS – FROM R&D COMPANY TO GLOBAL ONCOLOGY PLAYER? Nov 7, 2025 | Phase III results from HARMONi-A presented at SITC 2025 Summit Therapeutics has delivered its biggest news to date – and it could be the starting shot for a new era. Together with Chinese Akeso, they have presented the final results from the Phase III study HARMONi-A, and it is nothing short of a breakthrough. What is it about? The study tested ivonescimab – a new type of bispecific antibody that combines immunotherapy (PD-1 inhibition) and anti-angiogenesis (VEGF inhibition) – in combination with chemotherapy for patients with EGFR-mutated lung cancer who no longer respond to TKI treatment. The results speak for themselves: - Median overall survival: Ivonescimab + chemo: 16.8 months Chemo alone: 14.1 months - Hazard ratio (OS): 0.74 → 26% lower risk of death - Statistically significant (p=0.019) - >40,000 patients already treated in China 🇨🇳 Approved in China (May 2024) + NRDL-listed 🇺🇸 FDA Fast Track status → BLA application planned Q4 2025 Why is this so big for Summit? Summit has been a pure R&D company – without commercial products. Now they have: - A product with proven survival benefit - A unique mechanism of action that succeeds where other immunotherapies have failed - A regulatory path into the USA and Europe - Several ongoing Phase III studies globally (e.g., against Keytruda) And not least – strong owner support: Summit's largest owner and chairman of the board is Robert W. Duggan – a billionaire with an impressive track record in biotech. He was previously CEO and largest owner of Pharmacyclics, which was sold to AbbVie for 21 billion USD. Duggan has invested hundreds of millions of dollars in Summit and is deeply involved in the company's strategy. His financial muscle and experience give Summit both stability and credibility ahead of a potential commercialization. Conclusion: This is a milestone. Summit is on the threshold of becoming a global player in oncology. If FDA approval comes in 2026, ivonescimab could become the new standard in second-line treatment of EGFR-mutated NSCLC – a market with great need and low competition. This is not just a data point – it is a strategic shift. Summit is moving from the lab to the market. With Duggan at the helm and a rapidly growing pipeline, the potential is enormous.
- ·20.10.2025Yesterday (October 19th) Summit Therapeutics released a press release https://www.smmttx.com/wp-content/uploads/2026/10/2025_PR_1019_ESMO-HARMONi-6-Data-_-FINAL.pdf. This press release announces a major clinical breakthrough in lung cancer treatment. The drug ivonescimab (from Akeso and Summit Therapeutics) has been shown in a large Phase III study (HARMONi-6) to be superior to the current gold standard for a specific patient group. Here are the key points: The New Mechanism: Ivonescimab is not just another immunotherapy. It is a bispecific antibody, which means it is designed to attack cancer in two ways at once: PD-1 blockade: Activates the body's own immune system to attack cancer cells (the same mechanism as blockbusters like Keytruda). VEGF blockade: Prevents the tumor from forming new blood vessels, which effectively "starves" it (same mechanism as Avastin). The breakthrough (This is the key): The study was a direct comparison ("head-to-head") against the best available treatment today: a PD-1 inhibitor (Tislelizumab) plus chemotherapy. Ivonescimab won this comparison by a wide margin. Effect: The risk of the disease getting worse (progression) or the patient dying was reduced by 40%. Summary conclusion: This is the first time a Phase III study has shown that a new treatment is significantly better than the current gold standard (PD-1 + chemotherapy) for this patient group. The dual PD-1/VEGF effect appears to be a superior strategy. My reflection on the press release from Summit Therapeutics (SMMT) and their partner Akeso regarding their Phase III study (HARMONi-6) for the drug ivonescimab. The data, presented at ESMO and published in The Lancet, is exceptionally strong and represents a potential paradigm shift in the treatment of lung cancer (squamous NSCLC). Here is my immediate analysis of the possible scenarios: 1. The Positive Scenario (Opportunity) This is the first drug ever to be shown to be significantly better than the current gold standard (PD-1 inhibitors such as Keytruda + chemotherapy) in a Phase III trial. Superior Efficacy: Ivonescimab + chemotherapy reduced the risk of disease progression or death by 40% compared to standard therapy. Extended Disease-Free Survival: Patients achieved 11.14 months of progression-free survival (PFS), compared to just 6.90 months for standard therapy. This is a massive clinical gain. Blockbuster potential: If this result can be replicated globally, ivonescimab has the potential to replace the current standard of care and become the new global first-line treatment, representing a multi-billion dollar (USD) market. Broad Use: The drug is effective regardless of the patient's PD-L1 status, making it easy for doctors to prescribe to a broad patient population without the need for additional testing. 2. The Downside (Risk & Catch) The most important limitation, defining the entire investment risk, is that HARMONi-6 is a 100% Chinese study, sponsored and analyzed by the Chinese partner Akeso. Regulatory Obstacle: Neither the FDA (US) nor the EMA (Europe) will approve a drug for the global market based on this data alone. It all depends on HARMONi-3: The global value of Summit (SMMT) is entirely dependent on the ongoing global HARMONi-3 study. This study must replicate (repeat) the strong results from China. Long Timeline: We won't know the answer soon. Data from HARMONi-3 is not expected until the second half of 2026. This means a long wait and high risk until then. 3. Likely Scenarios Ahead Short Term (6-12 months): Akeso gets fast-track approval in China based on the HARMONi-6 data. Ivonescimab becomes the new standard of care in China, generating revenue there. Medium Term (2025-2026): The market will be extremely focused on the recruitment rate in the global HARMONi-3 study. Any delays will punish the stock. Competitors (Merck, BMS, etc.) will accelerate their own programs to try to catch up. Long Term (H2 2026 and beyond): Everything is decided. If HARMONi-3 succeeds: Summit has one of the biggest oncology successes in years and the stock revalues accordingly. If HARMONi-3 fails: The drug remains a Chinese concern and the global value for Summit is minimal. Summary: Today's data is a huge proof-of-concept that proves the drug's mechanism (PD-1/VEGF) is superior to the current standard. The potential is huge, but the risk is equally great and rests entirely on whether the results can be replicated in the global HARMONi-3 trial in 2026.
- ·9.10.2025An interesting case in oncology – Summit Therapeutics. The company is in late clinical phase with a unique drug candidate and has several triggers that could drive the share price significantly in the coming year. What does the company do? Summit is developing ivonescimab – a bispecific antibody that combines PD-1 and VEGF blockade in one molecule. It has shown better efficacy than Keytruda in certain lung cancer groups and is already approved in China. Highlights that speak for success: - Positive phase III data (PFS) globally - Two regulatory approvals in China - Collaboration with Pfizer and Revolution Medicines - Management with a proven track record, Robert Duggan (75%) and Maky Zanganeh (5%) are both owners and co-CEOs. They previously built Pharmacyclics (Imbruvica) which was sold for $21 billion. Their experience and capital strength are a great asset. - Strong cash ($298 mn) and insider support - First in class with PD-1/VEGF bispecific - Presentations at WCLC, ASCO, ESMO - Rumors of licensing deal with AstraZeneca Financial situation: Runway ~12–18 months. Issue risk exists, but insiders have historically supported capital raising. Summit is well positioned to raise capital on its own terms. Triggers in the coming year: - Interim data from HARMONi-3/HARMONi-7 - FDA acceptance of BLA application - Licensing deal with Big Pharma - New approvals or indications - Acquisition rumors, the 15 largest pharmaceutical companies have $535 billion on the sidelines for research and acquisitions - Presentations at ASCO/ESMO - Insider buyout or issuance with strong participation Summit is a classic high-risk/high-reward biotech case with exceptional upside if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15,11VWAP
Alin
14,04VaihtoMäärä
40,1 2 708 912
VWAP
Ylin
15,11Alin
14,04VaihtoMäärä
40,1 2 708 912
Välittäjätilasto
Dataa ei löytynyt